Imunon (IMNN) Interest & Investment Income (2010 - 2026)
Imunon's (IMNN) quarterly Interest & Investment Income came in at $57530.0 in Q1 2026, up 34.4% YoY from $42804.0 in Q1 2025, and up 48.07% on a QoQ basis from $38853.0 in Q4 2025.
Imunon (IMNN) Interest & Investment Income (2010 - 2026) Analysis & Trends
Imunon (IMNN) has 17 years of Interest & Investment Income data on file, last reported at $57530.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 34.4% year-over-year to $57530.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $170392.0 (down 63.98% YoY) and the FY2025 annual result came in at $155666.0, down 69.61% from the prior year.
- Interest & Investment Income advanced to $57530.0 in Q1 2026, from $38853.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $427454.0 in Q3 2023 to a low of -$236373.0 in Q4 2023.
- A 5-year average of $113985.4 and a median of $81921.0 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income jumped 11663.04% — and 2023, when it plunged 195.47%.
- Tracing IMNN's Interest & Investment Income over 5 years: stood at $247596.0 in 2022, then slumped by 195.47% to -$236373.0 in 2023, then jumped by 137.63% to $88957.0 in 2024, then tumbled by 56.32% to $38853.0 in 2025, then surged by 48.07% to $57530.0 in 2026.
- The last three Interest & Investment Income figures came in at $57530.0 (Q1 2026), $38853.0 (Q4 2025), and $46704.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Imunon | 8.42 Mn | 8.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57,530.00 |
| Dec 31, 2025 | 38,853.00 |
| Sep 30, 2025 | 46,704.00 |
| Jun 30, 2025 | 27,305.00 |
| Mar 31, 2025 | 42,804.00 |
| Dec 31, 2024 | 88,957.00 |
| Sep 30, 2024 | 115,992.00 |
| Jun 30, 2024 | 225,334.00 |
| Mar 31, 2024 | 81,921.00 |
| Dec 31, 2023 | -236,373.00 |
| Sep 30, 2023 | 427,454.00 |
| Jun 30, 2023 | 314,845.00 |
| Mar 31, 2023 | 253,070.00 |
| Dec 31, 2022 | 247,596.00 |
| Sep 30, 2022 | 153,301.00 |
| Jun 30, 2022 | 40,355.00 |
| Mar 31, 2022 | 12,104.00 |
| Dec 31, 2021 | 5,382.00 |
| Sep 30, 2021 | 3,552.00 |
| Jun 30, 2021 | -349.00 |